MSD announced Q3 results with 9-month revenue reaching USD 48.6 billion, including pharmaceutical sales of USD 43.3 billion despite a 68% China market decline to USD 1.5 billion. Between Q1 and Q3, Keytruda (pembrolizumab) sales grew 8% to USD 23.3 billion while human papillomavirus vaccine (HPV) franchise Gardasil decreased 40% to USD 4.2 billion due to competitive pressure in China from a domestic 9-valent vaccine. New product performances included pulmonary arterial hypertension (PAH) therapy Winrevair (sotatercept) achieving USD 976 million and pneumococcal vaccine Capvaxive generating USD 480 million since its June 2024 launch.

Pipeline advancements featured positive Phase III results for oral PCSK9 inhibitor enlicitide decanoate in hypercholesterolaemia and respiratory syncytial virus (RSV) monoclonal antibody (mAb) clesrovimab approval for infant prophylaxis with weight-independent dosing. HIF-2 alpha inhibitor Welireg (belzutifan) grew 42% to USD 496 million with ongoing expansion in renal cell carcinoma (RCC) indications. MSD maintained full-year guidance, expecting USD 64.5 to 65.0 billion revenue reflecting stabilising Keytruda growth offset by HPV vaccine competition and cardiovascular and metabolic portfolio contributions from newer assets, including GLP-1/glucagon dual agonist efinopegdutide advancing through clinical development.

According to PharmCube's NextBiopharm® database, Gardasil sales started their decline last year. Click here to request a free trial for NextBiopharm®.